BrainsWay Announces Strategic Collaboration with Mindful Health Solutions
BrainsWay has entered into a strategic collaboration with Mindful Health Solutions to expand patient access to its Deep TMS and SWIFT treatment protocols.
Stocks · News reference
BrainsWay Expands U.S. Insurance Coverage for Deep TMS Treatment of OCD
BrainsWay Ltd. announced an expansion in the number of U.S. medical insurance policies covering its Deep TMS treatment for obsessive-compulsive disorder (OCD), now reaching over 118 million Americans.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BrainsWay to Report Third Quarter 2026 Financial Results on November 10, 2026
BrainsWay Ltd. announced it will release its financial results for the third quarter of 2026 before the U.S. market opens on November 10, 2026.
HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $19 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BrainsWay (NASDAQ:BWAY) with a Buy and maintains $19 price target.
BrainsWay, Inland Psychiatric Collaborate On Multi-System Deep TMS Deployment And Mental Health Research Initiatives
BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced non-invasive neurostimulation treatments for mental health disorders, today announced a strategic
Bumble, Fermi, Xtend AI Robotics And Other Big Stocks Moving Higher On Tuesday
U.S. stocks mostly fell; Bumble surged 56.7% on Ithaca’s $6.05 buyout offer, while Fermi, Enerflex, BigBear.ai and others gained.
BrainsWay Says Over 70M U.S. Covered Lives Now Have Access To Policies Covering SWIFT Accelerated Depression Treatment